Key Highlights

  • FDMT rose 10.48% on 29 May 2026 to $9.91 on relative Volume of 5.96x, driven by gene-therapy sector momentum following Replimune's FDA alignment on resubmission.
  • Trading volume reached 3.32M shares as broader biotech sentiment improved on FDA priority-review signal for oncology gene therapy applications.
  • The move occurred during a record-setting US market session led by AI infrastructure enthusiasm, providing a supportive backdrop for small-cap biotech inflows.

About 4D Molecular Therapeutics Inc.

4D Molecular Therapeutics (Nasdaq:FDMT) develops AAV gene therapies targeting diseases of the eye, heart, and lung. The $518.06M market-cap biotech operates in the clinical-stage gene therapy space with exposure to sector-wide sentiment shifts and regulatory catalysts.

4D Molecular Therapeutics closed Friday, 29 May 2026 at $9.91, up 10.48% on volume of approximately 3.32 million shares with relative volume of 5.96x. Market cap closed near $518.06 million, positioning FDMT in small-cap biotech territory with trailing twelve-month EPS of $2.66.

Gene Therapy Sector Rally: Replimune as Catalyst

The primary driver of FDMT's 10.48% advance was a broader gene-therapy small-cap rally triggered by Replimune (NASDAQ:REPL) announcement on 29 May that the FDA had aligned on a resubmission path for the RP1 BLA (Biologics License Application) in advanced melanoma, with priority review indicated. The regulatory signal was interpreted by investors as constructive engagement and de-risking for the oncology gene therapy segment. FDMT, a pure-play AAV gene therapy name with clinical Assets in ophthalmology, cardiology, and pulmonology, drew flows from the improved sector sentiment.

Peers including Quidel (NASDAQ:QURE), Tenaya Therapeutics (NASDAQ:TNGX), Crescent Cove Therapeutics (NASDAQ:CCCC), Immuron (NASDAQ:IMRX), and Avrobio (NASDAQ:AVBP) also moved higher on similar mechanics.

Record-Setting Market Backdrop and AI Infrastructure Rally

The 29 May session was a record-setting day for US benchmarks on the back of an AI-infrastructure rally. The Dow Jones Industrial Average rose 0.72% to 51,032.46, the S&P 500 climbed 0.22% to 7,580.06, and the Nasdaq Composite added 0.2% to close at 26,972.62 , all three notching fresh records. The month of May saw the Nasdaq advance more than 8%, the S&P 500 climb roughly 5%, and the Dow add almost 3%. The rally was initiated on 28 May when Snowflake (NYSE:SNOW) reported its best quarter since its 2020 IPO, surging 36%, and Dell Technologies (NYSE:DELL) posted record $24.4 billion in AI server orders, rising nearly 33%. This constructive macro backdrop, combining lower Inflation expectations and stable rates with AI hardware momentum, supported risk-on flows across multiple sectors, including small-cap biotech.

Volume and Technical Setup

Trading volume of 3.32M shares represented relative volume of 5.96x, indicating materially elevated institutional and speculative interest. Relative volume above 2.0x typically signals strong momentum, while readings above 5.0x suggest potential for follow-through or consolidation in subsequent sessions. A tight close near session highs on heavy volume often attracts additional buying on the following Monday open, though sharp single-day rallies frequently see partial Retracement. The stock's support level will be the prior session's close; sustained moves below that level would weaken near-term momentum, while fresh highs above $9.91 would confirm continuation.

Clinical-Stage Risk and Capital Considerations

FDMT's trailing twelve-month EPS of $2.66 reflects ongoing clinical-stage Investment spending. For gene therapy names without near-term Revenue inflection, balance-sheet strength, cash runway, share count dilution, and regulatory de-risking become critical valuation drivers. Investors should monitor upcoming SEC filings, any shelf registrations, recent Equity raises, and management commentary on cash position and clinical milestones. Sector momentum can reverse quickly if peer clinical updates disappoint or regulatory signals shift.

What Matters Next

Watch for FDMT's next scheduled Earnings release, SEC filings on EDGAR, clinical-trial updates, broader biotech sector news, and price action relative to the 29 May close of $9.91. Related AI-infrastructure earnings from HPE (NYSE:HPE) on 1 June, Palo Alto Networks (NASDAQ:PANW) on 2 June, and data-center names on 4 June may continue to shape small-cap biotech positioning. Federal Reserve communications and inflation prints can also influence risk sentiment broadly.